RECURSION PHARMACEUTICALS, INC. business relationships

Companies named in RECURSION PHARMACEUTICALS, INC.’s 10-K filed 2026-02-25, and public companies whose annual reports name RECURSION PHARMACEUTICALS, INC.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 7.7 / 10
AI naming: 100 / 100
Agent readiness: 5 / 100
AI adoption: 14 / 100

Named in RECURSION PHARMACEUTICALS, INC.’s annual report 15

BayerLicensor7.7
“Bayer may terminate each such license agreement at any time without cause.” SEC filing
Roche GroupLicensor7.7
“In December 2021, Recursion entered into a collaboration and license agreement with Roche and Genentech (collectively referred to as Roche).” SEC filing
TAKEDA PHARMACEUTICAL CO LTD (TAK)Licensor7.7
“As a result, REC-4881 was in-licensed from Takeda and subsequently advanced into preclinical studies.” SEC filing
BayerPartner7.7
“In November 2023, we announced an amended and restated collaboration with Bayer.” SEC filing
Merck & Co., Inc. (MRK)Partner7.7
“In September 2023, we entered into a collaboration with Merck KGaA, Darmstadt, Germany.” SEC filing
NVIDIA CORP (NVDA)Partner7.7
“We largely train models using our own supercomputer, BioHive-2, one of the largest supercomputers in biopharma, built in collaboration with NVIDIA.” SEC filing
Roche GroupPartner7.7
“Under the collaboration, Roche and Genentech may initiate up to forty (40) small molecule programs.” SEC filing
TAKEDA PHARMACEUTICAL CO LTD (TAK)Partner7.7
“During a collaboration with Takeda, we leveraged machine learning and automated analysis to quantify hundreds of cellular parameters linked to APC siRNA knockdown.” SEC filing
Sanofi (SNY)Licensor6.7
“In January 2022, we entered into a Collaboration and License Agreement, with Sanofi, or the CLA, and in July 2023 and December 2023, we amended the Collaboration and License Agreement, with such as amended CLA referred to as the Amended CLA.” SEC filing
Sanofi (SNY)Partner6.7
“For the year ended December 31, 2025, the increase in revenue compared to the prior year was due to revenue recognized from our partnership with Sanofi.” SEC filing
AMAZON COM INC (AMZN)Supplier6.6
“We rely on third-party data centers and telecommunications solutions, including cloud infrastructure services such as Google Cloud and Amazon Web Services, to host substantial portions of our technology platforms and to support our business operations.” SEC filing
Alphabet Inc. (GOOGL)Partner5.5
“In October 2024, we announced an expanded collaboration with Google Cloud leveraging their technologies to accelerate drug discovery research and further enhance our ability to bring new medicines to patients faster.” SEC filing
Alphabet Inc. (GOOGL)Supplier5.5
“We rely on third-party data centers and telecommunications solutions, including cloud infrastructure services such as Google Cloud and Amazon Web Services, to host substantial portions of our technology platforms and to support our business operations.” SEC filing
Genentech, IncLicensor4.7
“On December 5, 2021, we entered into a Collaboration and License Agreement with Genentech, Inc. and F.” SEC filing
Genentech, IncPartner4.7
“Under the collaboration, Roche and Genentech may initiate up to forty (40) small molecule programs.” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.